SEC Comment Letter for ORAGENICS INC (OGEN) (CIK 0001174940) (OGEN) — Jan 6, 2020
ORAGENICS INC (OGEN) (CIK 0001174940)
Date: Jan. 6, 2020 · CIK: 0001174940 · Accession: 0000000000-20-000100
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235763
Letter
January 6, 2020 Alan F. Joslyn, Ph.D. Chief Executive Officer Oragenics, Inc. 4902 Eisenhower Blvd., Suite 125 Tampa, FL 33634 Re:Oragenics, Inc. Registration Statement on Form S-3 Filed December 31, 2019 File No. 333-235763 Dear Dr. Joslyn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark Catchur, Esq.
Show Raw Text
January 6, 2020
Alan F. Joslyn, Ph.D.
Chief Executive Officer
Oragenics, Inc.
4902 Eisenhower Blvd., Suite 125
Tampa, FL 33634
Re:Oragenics, Inc.
Registration Statement on Form S-3
Filed December 31, 2019
File No. 333-235763
Dear Dr. Joslyn:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mark Catchur, Esq.